<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00973908</url>
  </required_header>
  <id_info>
    <org_study_id>WWL - CDiff Prevention</org_study_id>
    <secondary_id>EUDRACT 2008-005244-16</secondary_id>
    <nct_id>NCT00973908</nct_id>
  </id_info>
  <brief_title>Probiotics for the Prevention of Antibiotics Associated Diarrhoea and Clostridium Difficile Associated Diarrhoea</brief_title>
  <official_title>Probiotics for the Prevention of Antibiotics Associated Diarrhoea and Clostridium Difficile Associated Diarrhoea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Health Service, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wrightington, Wigan and Leigh NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>South London and Maudsley NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Bristol NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hull and East Yorkshire Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Health Service, United Kingdom</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to investigate whether the routine use of the probiotic formulation
      VSL#3 co-prescribed with antibiotics reduces the incidence of both Antibiotic associated
      diarrhoea and Clostridium Difficile associated diarrhoea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators aim to find out whether VSL#3 can prevent Antibiotic associated diarrhoea
      and Clostridium Difficile associated diarrhoea when VSL#3 is giving during a course of
      systemic antibiotics. Patients will be randomized in a 1:1 proportion to receive either one
      sachet of VSL#3 or a similar looking placebo twice a day. This will be given for the length
      of the antibiotic course and another week thereafter. Follow-up will last until 28 days after
      the last antibiotic dose. Patient restarted on antibiotics during follow-up will be restarted
      on the trial medication and the 28 day follow-up will be recommenced.

      This trial has 2 co-primary outcome measures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of antibiotic associated diarrhoea</measure>
    <time_frame>28 days post last antibiotic dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Development of Clostridium difficile associated diarrhoea</measure>
    <time_frame>28 days post last antibiotic dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>28 days post last antibiotic dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day Mortality</measure>
    <time_frame>30 days after initiation of therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">231</enrollment>
  <condition>Diarrhoea</condition>
  <arm_group>
    <arm_group_label>VSL#3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive one VSL #3 sachets twice a day for the duration of the antibiotic course and for one week after.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will one placebo sachet twice a day for the duration of the antibiotic course and for one week after.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VSL#3</intervention_name>
    <description>Patients will o receive one VSL #3 sachets twice a day for the duration of the antibiotic course and for one week after.</description>
    <arm_group_label>VSL#3</arm_group_label>
    <other_name>Bifidobacterium breve</other_name>
    <other_name>Bifidobacterium longum</other_name>
    <other_name>Bifidobacterium infantis</other_name>
    <other_name>Lactobacillus acidophilus</other_name>
    <other_name>Lactobacillus plantarum</other_name>
    <other_name>Lactobacillus paracasei</other_name>
    <other_name>Lactobacillus bulgaricus</other_name>
    <other_name>Streptococcus thermophilus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will one placebo sachet twice a day for the duration of the antibiotic course and for one week after.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Maltose based Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged 18 or older

          -  Hospital inpatients

          -  On systemic antibiotics for an infection

          -  Antibiotics started within last 48 hours

        Exclusion Criteria:

          -  Diarrhoea at screening

          -  Unable to take enteral meds

          -  Patients on intensive care units

          -  Severe Immunosuppression (neutropenia, AIDS, congenital immunoparesis, chemotherapy)

          -  Risk of endocarditis (Artificial heart valves, history of rheumatic heart disease or
             infective endocarditis)

          -  Regular consumption of probiotics until 1 week prior to admission

          -  Acute severe pancreatitis Persistent vomiting (two days or more)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Haslam</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wirghtington Wigan and Leigh NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Albert Edward Infirmary</name>
      <address>
        <city>Wigan</city>
        <state>Lancashire</state>
        <zip>WN1 2NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Woolwich</city>
        <state>London</state>
        <zip>SE18 4QH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frenchay Hospital</name>
      <address>
        <city>Bristol</city>
        <zip>BS16 1LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hull Royal Infirmary</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weston General Hospital</name>
      <address>
        <city>Weston-super-Mare</city>
        <zip>BS23 4TQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Bergogne-Bérézin E. Treatment and prevention of antibiotic associated diarrhea. Int J Antimicrob Agents. 2000 Dec;16(4):521-6. Review.</citation>
    <PMID>11118872</PMID>
  </reference>
  <reference>
    <citation>D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ. 2002 Jun 8;324(7350):1361. Review.</citation>
    <PMID>12052801</PMID>
  </reference>
  <reference>
    <citation>Cremonini F, Di Caro S, Nista EC, Bartolozzi F, Capelli G, Gasbarrini G, Gasbarrini A. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2002 Aug;16(8):1461-7. Review.</citation>
    <PMID>12182746</PMID>
  </reference>
  <results_reference>
    <citation>Selinger CP, Bell A, Cairns A, Lockett M, Sebastian S, Haslam N. Probiotic VSL#3 prevents antibiotic-associated diarrhoea in a double-blind, randomized, placebo-controlled clinical trial. J Hosp Infect. 2013 Jun;84(2):159-65. doi: 10.1016/j.jhin.2013.02.019. Epub 2013 Apr 22.</citation>
    <PMID>23618760</PMID>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2009</study_first_submitted>
  <study_first_submitted_qc>September 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2009</study_first_posted>
  <last_update_submitted>April 25, 2013</last_update_submitted>
  <last_update_submitted_qc>April 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Health Service, United Kingdom</investigator_affiliation>
    <investigator_full_name>Christian Selinger</investigator_full_name>
    <investigator_title>Coordinating investigator</investigator_title>
  </responsible_party>
  <keyword>Clostridium difficile associated diarrhoea</keyword>
  <keyword>antibiotic associated diarrhoea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

